Ligand Pharmaceuticals (NASDAQ:LGND) Posts Quarterly Earnings Results, Beats Expectations By $0.56 EPS

Ligand Pharmaceuticals (NASDAQ:LGND) posted its earnings results on Thursday. The biotechnology company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.56, FiscalAI reports. The company had revenue of $59.67 million for the quarter, compared to analyst estimates of $55.59 million. Ligand Pharmaceuticals had a net margin of 46.42% and a return on equity of 14.50%. The firm’s revenue was up 39.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.27 EPS. Ligand Pharmaceuticals updated its FY 2026 guidance to 8.000-9.000 EPS.

Here are the key takeaways from Ligand Pharmaceuticals’ conference call:

• Ligand delivered a breakout 2025 with adjusted EPS up 42% and royalty revenue up 48%, reporting core revenue of $240M (ex‑Pelthos) and ending the year with over $1 billion in deployable capital.
• Commercial royalties from FILSPARI, Ohtuvayre, CAPVAXIVE and QARZIBA were the primary growth drivers (FILSPARI US sales $322M; Ohtuvayre ~ $506M; CAPVAXIVE $755M FY), supporting continued royalty scaling into 2026.
• Palvella’s QTORIN rapamycin produced highly significant Phase 3 MLM results with strong tolerability, setting up an NDA in H2 2026 and a potential first‑in‑class approval that Ligand estimates could translate to roughly $100M–$300M peak annual royalties.
• Management reaffirmed 2026 guidance (adjusted EPS $8–$9; royalty revenue $200–$225M) but cautioned the midpoint growth is muted by a 2025 one‑time out‑license fee and a modest, risk‑adjusted $4M FSGS royalty assumption reflecting a delayed PDUFA.
• Ligand is accelerating business development and has launched a systematic portfolio‑management approach, adding late‑stage opportunities (e.g., lasofoxifene, Castle Creek D‑Fi) intended to drive further royalty growth and deal origination.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ LGND traded up $2.14 during trading on Friday, reaching $198.31. 208,708 shares of the stock traded hands, compared to its average volume of 174,864. The company has a debt-to-equity ratio of 0.47, a current ratio of 24.69 and a quick ratio of 24.30. The stock has a market capitalization of $3.90 billion, a P/E ratio of 34.02 and a beta of 1.14. Ligand Pharmaceuticals has a 52-week low of $93.58 and a 52-week high of $212.49. The company has a 50-day moving average of $193.46 and a 200-day moving average of $185.36.

Trending Headlines about Ligand Pharmaceuticals

Here are the key news stories impacting Ligand Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — non-GAAP EPS $2.02 vs. $1.46 est. and revenue $59.7M vs. $55.6M est.; revenue rose ~39.5% year-over-year, underpinning near-term momentum. Earnings Beat Article
• Positive Sentiment: Management issued very strong FY2026 guidance: adjusted EPS $8.00–$9.00 (vs. consensus ~$4.85) and revenue $245M–$285M (around consensus), signaling meaningful upside to street profitability expectations. Press Release
• Positive Sentiment: Analyst support: Oppenheimer raised its price target to $277 and kept an “outperform” rating, pointing to significant upside from current levels. Analyst Note
• Positive Sentiment: Longer-term growth thesis reinforced — company projects a ~23% CAGR in royalty revenues through 2030 and reported ~48% full-year royalty revenue growth for 2025, supporting durable cash-flow expectations. Royalty Growth Outlook
• Neutral Sentiment: Earnings-call materials and transcripts are available for detail review — useful to confirm drivers (one-time items, royalty composition, cadence of royalty receipts). Review the call transcript and highlights for management color. Earnings Call Transcript Earnings Highlights
• Neutral Sentiment: Other analysts voiced bullish views (e.g., HC Wainwright), which can support sentiment but are not new fundamental data. Analyst Commentary
• Negative Sentiment: Some short-term selling pressure was reported (an article noted ~6% intraday weakness) — likely profit-taking and valuation concerns (LGND’s high P/E) after sharp moves; monitor whether investors question sustainability of the elevated EPS guidance or attribute upside to non-recurring items. Why Stock Fell

Insider Transactions at Ligand Pharmaceuticals

In related news, CFO Octavio Espinoza sold 1,804 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $188.31, for a total value of $339,711.24. Following the completion of the transaction, the chief financial officer directly owned 26,186 shares of the company’s stock, valued at approximately $4,931,085.66. This trade represents a 6.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John W. Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $195.91, for a total transaction of $91,489.97. Following the completion of the transaction, the director owned 43,187 shares of the company’s stock, valued at $8,460,765.17. This represents a 1.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,205 shares of company stock worth $611,192 over the last 90 days. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ligand Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Maryland State Retirement & Pension System boosted its holdings in shares of Ligand Pharmaceuticals by 2.2% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,872 shares of the biotechnology company’s stock worth $543,000 after acquiring an additional 61 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in Ligand Pharmaceuticals by 86.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 69 shares in the last quarter. Cerity Partners LLC boosted its stake in Ligand Pharmaceuticals by 5.4% in the 4th quarter. Cerity Partners LLC now owns 1,531 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 79 shares during the period. Blair William & Co. IL grew its holdings in Ligand Pharmaceuticals by 1.0% during the 4th quarter. Blair William & Co. IL now owns 8,474 shares of the biotechnology company’s stock valued at $1,602,000 after buying an additional 88 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in Ligand Pharmaceuticals by 1.3% during the 4th quarter. Wellington Management Group LLP now owns 8,426 shares of the biotechnology company’s stock valued at $1,593,000 after buying an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 91.28% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on LGND shares. HC Wainwright upped their price target on Ligand Pharmaceuticals from $231.00 to $239.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Ligand Pharmaceuticals in a report on Monday, December 29th. Royal Bank Of Canada raised their price target on shares of Ligand Pharmaceuticals from $234.00 to $235.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Oppenheimer increased their price objective on shares of Ligand Pharmaceuticals from $275.00 to $277.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Citigroup began coverage on Ligand Pharmaceuticals in a research note on Tuesday, December 9th. They issued a “buy” rating and a $270.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.17.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.